Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
Autoimmune Disorders01:29

Autoimmune Disorders

2.4K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Analysis of clinical characteristics of renal oncocytoma: 26 cases report].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2012
Same author

[Expression of Na+/H+ antiporter gene KsNHX1 in Kochia sieversiana under saline-alkali stress].

Ying yong sheng tai xue bao = The journal of applied ecology·2012
Same author

Fasudil, a Rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice.

International journal of molecular sciences·2012
Same author

[Analysis of genes and genetic susceptibility of olfactory disorders].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2012
Same author

Top-down processing of symbolic meanings modulates the visual word form area.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2012
Same author

Oxidative stress acts on special membrane proteins to reduce the viability of Pseudomonas syringae pv tomato.

Journal of proteome research·2012

Related Experiment Video

Updated: May 4, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.3K

Daclizumab for relapsing remitting multiple sclerosis.

Jia Liu1, Lu-Ning Wang, Siyan Zhan

  • 1Department of Geriatric Neurology, Chinese PLA General Hospital, Fuxing Road 28, Beijing, China, 100853.

The Cochrane Database of Systematic Reviews
|December 24, 2013
PubMed
Summary

Daclizumab did not show clear benefits over placebo for multiple sclerosis (MS) in clinical or MRI outcomes, though it was generally well-tolerated. Infections were the most common side effect in patients with relapsing-remitting MS (RRMS).

More Related Videos

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

17.7K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K

Related Experiment Videos

Last Updated: May 4, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.3K
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

17.7K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K

Area of Science:

  • Immunotherapy for neurological disorders
  • Autoimmune disease treatment

Background:

  • Monoclonal antibodies like daclizumab offer potential immunotherapy for multiple sclerosis (MS).
  • Daclizumab targets the interleukin-2 receptor alpha subunit (CD25), showing promise for relapsing-remitting MS (RRMS) patients.
  • This review updates previous analyses of daclizumab's efficacy and safety.

Purpose of the Study:

  • To evaluate the safety and efficacy of daclizumab in preventing clinical worsening in RRMS patients.
  • To compare daclizumab's effects against placebo and other treatments.

Main Methods:

  • Systematic search of randomized controlled trials (RCTs) evaluating daclizumab for RRMS.
  • Inclusion of trials comparing daclizumab (alone or combined) versus placebo or other therapies.
  • Independent data extraction and quality assessment by two reviewers.

Main Results:

  • Two RCTs with 851 RRMS patients were included, assessed as low risk of bias.
  • At 52 weeks, low-dose daclizumab showed a significant reduction in Expanded Disability Status Scale (EDSS) change compared to placebo (P=0.01).
  • Both low- and high-dose daclizumab significantly reduced new relapses (19-20%) versus placebo (36%) (P<0.0001, P=0.00032).
  • No increased risk of adverse or serious adverse events was observed; infections were the most frequent, manageable side effects.

Conclusions:

  • Insufficient evidence exists to confirm daclizumab's superiority over placebo for RRMS clinical and MRI outcomes.
  • Daclizumab demonstrated relative tolerability, with infections being the primary adverse events.
  • Further research is needed to clarify daclizumab's role in MS management.